Developing guidelines for 'omics'-based tests
23 July, 2014A new guide for 'omics'-based tests, focusing on genomic testing, has been released for public consultation by the NHMRC.
Virax appoints oncology guru to scientific board
21 July, 2014 by Dylan Bushell-EmblingVirax Holdings (ASX:VHL) has selected US cancer specialist Dr Joseph Sparano to lead phase I/IIb trials of breast cancer treatment candidate GGTI-2418.
Shutting the gate on the malaria parasite
18 July, 2014Blocking the malaria parasite's access to proteins needed for its survival may lead to the development of new treatments for this deadly disease.
New initiative for health research and its translation
17 July, 2014The NHMRC has launched the Advanced Health Research and Translation Centre initiative.
Prima picks up US patent for cancer treatment CVac
16 July, 2014 by Dylan Bushell-EmblingThe US patent office has approved Prima BioMed's (ASX:PRR) application for a patent protecting autologous cancer treatment candidate CVac.
Imugene picks exclusive manufacturer for HER-Vaxx
16 July, 2014 by Dylan Bushell-EmblingImugene (ASX:IMU) has selected Swiss-based virosome specialist Mymetics as the exclusive manufacturer for its HER-Vaxx cancer immunotherapy product.
Funding diabetes
11 July, 2014A new ARC Special Research Initiative for Type 1 juvenile diabetes will see $35 million committed to research into this disease.
Regeneus secures rights to cancer vaccine for humans
08 July, 2014 by Dylan Bushell-EmblingRegeneus (ASX:RGS) has picked up exclusive rights to an autologous therapeutic cancer vaccine for humans, after having already secured the exclusive licence for veterinary applications.
Imugene appoints new director
07 July, 2014 by Dylan Bushell-EmblingImugene's (ASX:IMU) second-largest shareholder, small caps investor Otto Buttula, has taken a seat on the company's board.
Sirtex achieves 10 years of quarterly sales growth
04 July, 2014 by Dylan Bushell-EmblingSirtex (ASX:SRT) hit a milestone during the June quarter, recording its 40th consecutive quarter of sequential growth in dose sales of its SIR-Spheres liver cancer treatment.
Talking medicine with Nobel laureates
26 June, 2014Fifteen young Australian medical researchers are off to Germany to meet with Nobel Prize winners in physiology and medicine.
Minomic relocates HQ to Macquarie Uni Hospital
23 June, 2014 by Dylan Bushell-EmblingMinomic International has moved its scientific HQ to Macquarie University Hospital, to help commercialise prostate cancer test MiSat ELISA and jointly develop new cancer screening technologies.
Alchemia enrols first patient for new mCRC trial
20 June, 2014 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has commenced recruitment for a clinical trial evaluating the use of HA-Irinotecan in combination with cetuximab in metastatic colorectal cancer.
Patrys picks up third US patent for PAT-SM6
19 June, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has been awarded a third US patent covering its cancer treatment candidate PAT-SM6, which is in clinical trials as a treatment for multiple myeloma.
Novogen, CanTx establish proof of concept for Trx-1
19 June, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) and its CanTx JV have published preclinical data supporting the potential of Trx-1, injected into the peritoneal cavity, as a first-line therapy for ovarian cancer.
